We previously described a gene signature for breast cancer stem cells (BCSCs) derived from patient biopsies. Selective shRNA knockdown identified ribosomal protein L39 (RPL39) and myeloid leukemia factor 2 (MLF2) as the top candidates that affect BCSC self-renewal. Knockdown of RPL39 and MLF2 by specific siRNA nanoparticles in patientderived and human cancer xenografts reduced tumor volume and lung metastases with a concomitant decrease in BCSCs. RNA deep sequencing identified damaging mutations in both genes. These mutations were confirmed in patient lung metastases (n = 53) and were statistically associated with shorter median time to pulmonary metastasis. Both genes affect the nitric oxide synthase pathway and are altered by hypoxia. These findings support that extensive tumor heterogeneity exists within primary cancers; distinct subpopulations associated with stem-like properties have increased metastatic potential.
We previously described a gene signature for breast cancer stem cells (BCSCs) derived from patient biopsies. Selective shRNA knockdown identified ribosomal protein L39 (RPL39) and myeloid leukemia factor 2 (MLF2) as the top candidates that affect BCSC self-renewal. Knockdown of RPL39 and MLF2 by specific siRNA nanoparticles in patientderived and human cancer xenografts reduced tumor volume and lung metastases with a concomitant decrease in BCSCs. RNA deep sequencing identified damaging mutations in both genes. These mutations were confirmed in patient lung metastases (n = 53) and were statistically associated with shorter median time to pulmonary metastasis. Both genes affect the nitric oxide synthase pathway and are altered by hypoxia. These findings support that extensive tumor heterogeneity exists within primary cancers; distinct subpopulations associated with stem-like properties have increased metastatic potential. L arge-scale sequencing analyses of solid cancers have identified extensive tumor heterogeneity within individual primary cancers (1) . Recent studies indicate that such tumoral heterogeneity is associated with heterogeneous protein function, which fosters tumor adaptation, treatment resistance, and failure through Darwinian selection (2) (3) (4) . Cancer stem cells are a subpopulation of cells within the primary tumor responsible for tumor initiation and metastases (5) (6) (7) (8) (9) . Three groups have recently independently provided functional evidence for the presence of cancer stem cells by lineage-tracing experiments (10) (11) (12) . These observations suggest that these subpopulations of cancer stem cells (CSCs) within the bulk primary tumor are resistant to conventional therapies through different adaptive mechanisms with the potential for self-renewal and metastases (7, 13, 14) . However, few studies have determined the genetic profile of the cells that escape the primary cancer and evolve in distant metastatic sites (1) . Additionally, no large-scale sequencing studies of metastases have been conducted because the majority of patients are treated with systemic therapies and not surgery.
Tumor clonal heterogeneity within a primary tumor may in part be explained by hypoxic regions within the bulk tumor that have been correlated with invasiveness, therapeutic resistance, and metastasis (15) (16) (17) (18) . Cancer stem cells have been found to reside near hypoxic regions in some solid cancers (19) (20) (21) . We have previously published a 477-gene tumorigenic signature by isolating breast cancer stem cells (BCSCs) derived from patient biopsies (22) . Here, we have identified two previously unidentified cancer genes, ribosomal protein L39 (RPL39) and myeloid leukemia factor 2 (MLF2), by selective shRNA knockdown of genes from this tumorigenic signature, that impact breast cancer stem cell self-renewal and lung metastases. Analysis of 53 patient lung metastases confirmed damaging mutations in RPL39 and MLF2 in a significant number of samples, which conferred a gain-of-function phenotype. These mutations were statistically associated with shorter median time to distant relapse. We further describe a common mechanism of action through nitric oxide synthase signaling that is regulated by hypoxia.
Results
Identification of siRNA Targets for Breast Cancer Stem Cells. As described in the Introduction, we have previously published a 477-gene tumorigenic signature of BCSC self-renewal derived from patient biopsies (22) . An shRNA library encompassing all 477 genes with the 2-3 shRNAs per gene was created, as previously published (23, 24) . Selfrenewal capacity using the mammosphere forming efficiency (MSFE) was assayed, with an empty vector shRNA and gamma secretase inhibitor (GSI) against the Notch pathway as controls. Two triple negative breast cancer cell lines, SUM159 and BT549, were treated with pGIPZ lentiviral particles, with eight biologic replicates. The MSFE was analyzed using a Wilcoxon rank sum test with 20% threshold for a positive hit (Fig. 1A) . The Notch pathway inhibitor GSI dramatically reduced mammosphere formation at 10 μM concentration (Fig. 1B) . A short list of target genes was then defined using Z score analysis, showing reduced MSFE in both cell lines of all shRNAs in the screen (Fig. 1C) . Only five
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The authors declare no conflict of interest. *This Direct Submission article had a prearranged editor. shRNAs showed significantly reduced expression in both SUM159 and BT549 cell lines (P < 0.05) (Fig. 1 C and D) . The statistically significant genes were rescreened with multiplicity of infection of 10 for n = 6 replicates, using both SUM159 and BT4549 cell lines (Fig. 1E) . Specifically, we chose the top two genes, RPL39 and MLF2, based on the effectiveness of down-regulation of BCSC renewal capacity by lentiviral shRNA knockdown of these two cell lines (SUM 159 and BT549) (Fig.  S1 ). These top two genes, RPL39 and MLF2, were then selected for further study.
To develop potential therapeutics, we then identified the corresponding siRNA sequence for RPL39 and MLF2. We tested target engagement for three siRNA sequences per gene in vitro (Fig. S2 ) and selected the optimal siRNA sequence for further studies. We then tested the specificity of the optimal siRNA using knockdown followed by rescue and analysis by quantitative reverse transcriptase polymerase chain reaction (q-RT-PCR) and Western analysis (Fig.  S3) . The optimal siRNAs were found to significantly reduce MSFE in three cell lines (Fig. 1F) .
In Vivo Xenograft Treatment Studies Show Significant Reduction in Tumor Volume and Improved Median Time to Survival with siRNAs Against RPL39 and MLF2. We initiated in vivo studies to measure the treatment efficacy of these siRNAs in MDAMB231 tumor xenografts. Significant reduction in tumor volume was observed in RPL39-and MLF2-treated groups, compared with vehicle-treated groups ( Fig. 2A) (P < 0.05, Mann-Whitney rank sum test). Additionally, the combination of RPL39/ MLF2 siRNAs with chemotherapy further significantly reduced tumor volume compared with docetaxel chemotherapy alone (Fig. 2B) (P < 0.05, Mann-Whitney rank sum test).
Next, to assess whether the combination of siRNA/docetaxel could improve survival, treatment was aborted after two cycles, and time to survival was measured. Most importantly, the combination of RPL39 or MLF2 siRNA with chemotherapy significantly prolonged median survival over chemotherapy alone (P < 0.05, Mann-Whitney rank sum test). (Fig. 2C) , mimicking the adjuvant setting in the treatment of early breast cancer with the maximum ability to impact survival in patients.
In Vivo Studies Demonstrate the Effect on BCSCs and Lung Metastasis with siRNAs Against RPL39 and MLF2. We conducted a series of shortterm studies to measure the effect of the siRNAs in a patient-derived human cancer triple negative breast cancer xenograft model (BCM2665) and further confirmed results in a second triple negative cell line model, SUM159. A multistage vector (MSV) liposomal nanoparticle delivery platform was used for sustained siRNA delivery with a single 2-wk dose (25) . Significant reduction in tumor volume was observed in BCM2665 treated with RPL39 and MLF2 siRNA alone (Fig. 2D , Left) and with the combination of siRNA plus docetaxel vs. docetaxel (20 mg/kg) (Fig. 2D, Right) . Similar results were obtained in SUM159 xenografts (Fig. S4 ). Significant reduction in secondary MSFE and nonsignificant decrease in Aldefluor due to the variability of marker with RPL39 and MLF2 siRNAs was observed (Fig. 2E ). The Aldefluor assay was used to assess BCSCs because the BCM2665 patient-derived model system does not express CD44
low/-cells (26) . Statistically significant reduction of Aldefluor in SUM159 xenograft (Fig. S4 ) was observed. Additionally, target engagement was demonstrated by immunohistochemical analysis of RPL39 siRNA-and MLF2 siRNA-treated samples in BCM2665 (Fig. 2F ) and SUM159 xenografts (Fig. S4) .
In vivo limiting dilution assays (LDAs), which determine tumor initiating capacity, were conducted with tumors from SUM159 and MDAMB231 xenografts treated in vivo with RPL39 and MLF2 siRNA. SUM159 vehicle-treated group yielded 10/12 tumors, with a significant decrease in RPL39-treated (2/12) as well as MLF2-treated groups (4/12) (P < 0.05, Fisher's exact test) at 5 wk with 50,000 cells. Similarly, with MDAMB231 xenografts, the vehicletreated group yielded 9/12 tumors, with a significant decrease in RPL39-treated (4/12) and MLF2-treated (2/12) xenografts (Fig.  2G ). These data were confirmed with a patient-derived xenograft (BCM 2665). The vehicle group yielded 9/10 tumors with a significant decrease in RPL39-treated (1/10) as well as MLF2-treated (0/ 10) groups at 3.5 wk with 50,000 cells (P < 0.05, Fisher's exact test). Similar significant results were seen with 200,000 cells (Fig. 2H) .
SCID-Beige mice were injected with luciferase-tagged MDAMB231 cells and treated with siRNA against RPL39 or MLF2 packaged in liposome nanoparticles twice weekly simultaneously, and then killed at week 6. A representative image of RPL39-and MLF2-treated mice 6 wk after primary-tumor injection is shown in Fig. 2H . All of the animals (12/12) treated with the scrambled siRNA group showed lung metastasis using in vivo International Veternary Information Service imaging whereas mice treated with RPL39 siRNA (5/11)and MLF2 siRNA (8/12) had significant reduction in lung metastasis (χ 2 test; RPL39, P < 0.05; MLF2, P < 0.05). Moreover, the luciferase analysis showed a significant reduction in the luminescence upon treatment with RPL39 and MLF2 siRNAs, respectively (P < 0.05) over time (Fig. 2I ).
Increase in Cell Migration, MSFE, and Proliferation with RPL39 and MLF2 Overexpression. Overexpression of RPL39 and MLF2 in both MDAMB231 and BT549 cells significantly increased the woundhealing capacity with concomitant increase in migration index (Fig.  3A) . Additionally, significant increase in secondary MSFE was observed, suggesting an important role for these genes in BCSC self-renewal (Fig. 3B) . We also observed a significant increase in proliferation ( Fig. 3C ) with overexpression of RPL39 and MLF2. To demonstrate specificity of signaling by NOS pathway, rescue experiments were performed. RPL39 and MLF2 plasmids were able to reverse the siRNA-induced reduction in wound-healing capacity ( Fig. S5 A and B) . 
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RPL39 and MLF2 Affect Nitric Oxide Synthase and Hypoxia Signaling
Pathway. Mutual-exclusivity analysis of RPL39 and MLF2 using The Cancer Genome Atlas (TCGA) breast cancer database determined that RPL39 and MLF2 co-occur at odds ratio of >10 (P = 0.02), suggesting a common mechanistic pathway (Fig. 4A ) (27) . Microarray analysis of siRNA-treated patient-derived human-cancer-inmice xenograft BCM2665 was then performed to determine alterations in gene expression, followed by Ingenuity Pathway Analysis of the top signaling pathways common to both RPL39 and MLF2 siRNA-treated samples. Differential expression of "cellular effects of sildenafil (Viagra)" reflecting the nitric oxide signaling pathway (Fig.  4 B and C and Tables S1 and S2) was present for both RPL39 and MLF2. Thus, we specifically analyzed the nitric oxide synthases [inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS)] and their impact on RPL39 and MLF2. Overexpression of RPL39 and MLF2 led to an increase in eNOS and iNOS signaling with no change in nNOS in three cell lines (Fig.  4D) . A clear reduction in iNOS signaling, together with decrease in eNOS without much change in nNOS, was observed with RPL39/ MLF2 siRNA treatment (Fig. 4E) . Next, rescue experiments were performed to test whether RPL39 and MLF2 were modulated in an NOS-dependent manner. These genes were overexpressed in two triple negative breast cancer cells lines, and NOS signaling was inhibited by NG-nitro-L-arginine methyl ester (L-NAME), a smallmolecule inhibitor for NOS. Wound healing induced by RPL39 and MLF2 genes was significantly reduced in the presence of L-NAME (Fig. 4F) , which was rescued using three molar excess of L-arginine, demonstrating a role of NOS signaling in both RPL39 and MLF2 (Fig.  4F) . Additionally, we observed that the reduction in wound healing capacity caused by siRNA against iNOS could be directly rescued by either RPL39 or MLF2 plasmid (Fig. S5 C and D) .
The relationship between nitric oxide synthase signaling and hypoxia has been well described in various tissue types (28) (29) (30) (31) . Hypoxia (1% O 2 ), in an HIF1α-dependent manner, induced RPL39 and MLF2 with concomitant increase in iNOS in two breast cancer cell lines (SUM159 and MDAMB231) (Fig. 5A) . Inhibition of NO signaling by specific iNOS inhibitor 1400W decreased expression of RPL39 and MLF2 in an HIF1α-dependent manner in two cell lines (MDAMB231 and SUM159) (Fig. 5B ). This inhibitor also decreased soluble guanylate cyclase (SCG) and cyclic-GMP dependent kinase-1 (PKG-1), which are directly downstream of NOS (Fig. 5B) whereas overexpression of RPL39 and MLF2 increased SGC and PKG-1, as expected in canonical iNOS-dependent signaling (Fig. 5B) . Additionally, overexpression of RPL39/MLF2 genes, followed by hypoxic (1% O 2 ) conditions, dramatically reduced HIF1α expression (Fig.  5C ), thus suggesting a potential feedback loop between HIF1α-dependent signaling and RPL39/MLF2 (Fig. 5F ). We next tested the correlation between RPL39/MLF2 and HIF1α hypoxia-related signaling in siRNA-treated human xenograft (BCM2665) using gene specific enrichment analysis (GSEA) (32) . Our results indicate a direct correlation between HIF1α-mediated hypoxia and RPL39/ MLF2 (Fig. 5 C and D) . The differential expression of five out of seven hypoxia-related genes (EIF1A1, ECE1, CAT, EPAS1, and SNRNP70) was confirmed by q-RT-PCR in patient-derived BCM2665 xenograft tumors (Fig. 5E ).
Mutations in RPL39 and MLF2 Are Detected in Patient Breast Cancer Lung Metastasis. As described in the Results subsection on the in vivo studies of lung metastasis, a significant reduction in lung metastases effect with siRNAs against RPL39 and MLF2 was observed in vivo, suggesting a potential role of these genes in metastasis. Eight patient deidentified lung metastases were obtained and analyzed for mutations in RPL39 and MLF2 gene using RNA deep sequencing. As shown in Fig. 6A , four damaging mutations were determined by SIFT (sorting intolerant from tolerant) analysis, two each in RPL39 (A14V and G50S) and MLF2 (D12H and R158W). Next, we tested whether these mutations conferred a gain-offunction. Wild type RPL39 and MLF2 overexpression vs. mutations were incorporated in plasmids for RPL39 (A14V and G50S) and MLF2 (D12H and R158W) in two triple negative cell lines. Representative images for wild-type (black arrows) and mutant (red arrows) competitive allele-specific TaqMan (CAST) PCR assays (Life Technologies) are shown in Fig. 6A . Increases in woundhealing capacity were confirmed with three mutations, RPL39 (A14V) and MLF2 (D12H and R158W), over the wild-type plasmid in a 4-h time frame (Fig. 6B and Fig. S6) .
Analyses of 477 primary breast cancers from The Cancer Genome Atlas (TCGA) CGHub (http://cghub.ucsc.edu) for mutations in either RPL39 or MLF2 were then conducted. Recently, mutation R158W in MLF2 was reported in non-small cell lung cancer (33), but not in breast cancer. We next tested the hypothesis of tumor heterogeneity within primary cancers and clonal selection with the small subpopulation of cells with stem-like properties showing increased metastatic propensity to the lung. Five matched primary and lung metastases were tested that were known to have mutations in RPL39 or MLF2 in lung metastases. Using CAST PCR (Life Technologies), no amplification was observed in all five individual primary tumors whereas mutations were identified in their matched lung metastatic pair. These data lend support to the observation that the frequency of the mutations may be too low in the primary tumors to be detected by conventional methods. Additionally, we tested these mutations by DNA-seq. Our results confirmed the lack of mutations in the primary samples, and 2/3 mutations were confirmed in the metastatic samples (Table S3) (34, 35) . Competitive allele-specific PCR is a robust technology to detect mutations in formalin-fixed paraffin-embedded samples as shown in Fig. 6 (36-38) .
Mutations in RPL39 (A14V) and MLF2 (D12H and R158W) Are Associated with Shorter Median Time to Relapse. In the clinical setting, resections of lung metastases are very rarely performed. We next examined mutations in RPL39 and MLF2 with competitive allele-specific PCR using genomic DNA derived from 53 patient lung metastases, with both estrogen receptor (ERα) positive and negative tumors. No significant difference in mutation frequency was observed according to steroid hormone receptor status (Fig.  6C) . We found mutation in 6/53 patients in A14V, 4/53 patients in D12H, and 12/53 in R158W (Fig. 6C) .
The time from initial diagnosis to lung metastasis was then assessed. Patients harboring gain-of-function mutations in RPL39 and MLF2 had a significantly shorter median time to relapse compared with those without mutations (P = 0.0259, χ 2 test) (Fig. 6D ).
Discussion
Relapse of primary breast cancer at a metastatic site is the major cause of death in patients. In this present study, we report the discovery of two relatively novel cancer genes, RPL39 and MLF2, and describe their importance in tumor initiation and metastasis. Recently, functional evidence for the presence of cancer stem cells was confirmed in glioblastomas (GBMs), squamous skin tumors, and intestinal adenomas (10) (11) (12) . To our knowledge, we were one of the first groups to describe that breast cancer stem cells demonstrate intrinsic resistance to conventional therapy in clinical samples (7, 22) . Since these initial observations, other groups have confirmed these findings following conventional chemotherapy or radiation therapy (39) . Metaanalyses of over 2,000 breast-cancer patients indicate that an increase in BCSC markers is significantly associated with an approximately threefold higher likelihood of metastases (5, 39) .
In the present study, we used a functional approach to identify previously unidentified targets for cancer stem cells. We previously isolated BCSCs by isolating CD44 + /CD24 low/-MS-forming cells from patient biopsies, and a tumorigenic signature of 477 genes (22) . shRNA knockdown followed by a confirmatory screen yielded two top candidates, RPL39 and MLF2. RPL39 has been described as component of the 60S ribosomal complex located on chromosome X (XQ24), with a proposed role in spermatogenesis and translation (40, 41) . MLF2 is located on chromosome 12 and may participate in chromosomal aberrations and defense response (42) . RPL39 may play a role in ribosome biogenesis, which has been implicated in tumor growth progression and transformation (43, 44) . Although almost nothing is known about the role of RPL39 in cancer, there is limited information available on MLF2. A series of amino acid modifications of MLF2 on Ser-144, -152, and -238 (45-47) and a somatic mutation (p.Phe80Cys) have been described in colorectal cancer (48) .
Therapeutically, siRNAs are more desirable than lentiviral shRNA. Using the sequences derived from shRNA screening, we designed siRNAs against the top two targets, RPL39 and MLF2. We demonstrated a significant tumor reduction in patient-derived human cancer xenograft tumors treated with siRNAs against RPL39/ MLF2 alone, as well as in combination with chemotherapy. More importantly, we found a significant benefit in prolonging median survival in the mice treated with a combination of chemotherapy and siRNA against RPL39/MLF2 compared with mice treated with chemotherapy alone. These siRNAs were effective in reducing cancer stem cells as defined by a reduction in MSFE, flow cytometry, and in limiting dilution assays. In these models, a profound impact on lung metastases with silencing RPL39 and MLF2 was observed, thus confirming the relevance of RPL39 and MLF2 in both tumor initiation and lung metastases.
Mutual exclusivity analysis using the TCGA database shared a highly statistically significant correlation between RPL39 and MLF2, suggesting a common mechanistic pathway. By Ingenuity Pathway Analysis, nitric oxide signaling was the top common pathway involved in the regulation of RPL39 and MLF2. Overexpression and knockdown of RPL39 and MLF2 demonstrated a concomitant change in iNOS. Importantly, nitric oxide synthase signaling, in particular iNOS, has been shown to play an important role in cancer stem cells and in other solid cancers like glioblastoma multiforme (49) . Increased iNOS production has been shown to predict poor survival in breast-cancer patients (50) . This study supports these previously published observations. A better understanding of the role of NO signaling in tumor tissues and stroma is essential to successfully target this pathway.
A relationship between NO signaling and hypoxia has been welldescribed (28) (29) (30) (31) . Cancer stem cells have been described to reside near hypoxic regions in solid cancers (19) (20) (21) . Hypoxia transcriptionally activates iNOS in an HIF1α-dependent manner and promotes metastases primarily through HIF1α (30) , which has been shown to regulate CD44 and its variants CD44v6, CD44v8, known markers of BCSCs (31) . In our study, hypoxia (1% O 2 ) mediated by HIF1α increased iNOS signaling, along with induction of RPL39 and MLF2. Inhibition of iNOS by 1400W, a specific inhibitor of iNOS, reduced RPL39 and MLF2 in a dose-dependent manner. Additionally, HIF1α was concomitantly reduced, suggesting cross-talk between iNOS and HIF1α that is modulated by RPL39 and MLF2. An opposite effect was observed when RPL39 and MLF2 were overexpressed with an increase in the downstream effectors of NOS signaling pathway, SGC and PKG-1. These data suggest that RPL39 and MLF2 play a critical role in the cross-talk between iNOS and HIF1α. Under hypoxic conditions (1% oxygen), overexpression of RPL39 and MLF2 led to a reduction in HIF1α, suggesting a role for RPL39 and MLF2 as a negative feedback mechanism in HIF1α signaling. Other groups have described hypoxia and the regulation of CSC self-renewal. Our data support the results from these seminal papers (51) (52) (53) (54) .
Interestingly, bulk primary tumors from The Cancer Genome Atlas did not describe these mutations in breast cancer. These mutations may be present in a small subpopulation of cells and may not be detected due to the depth of coverage. A 100-to 1,000-fold coverage is required to detect clinically relevant somatic mutations in small tumor subpopulations because primary tumors are heterogeneous and this intratumoral heterogeneity may prevent the identification of specific mutations in distinct subpopulations (1, 55) .
The gain-of-function mutations in RPL39 (AV14) and MLF2 (R158W and D12H) were present in a significant percentage of the lung metastases from 53 patients with both ERα-positive and ERα-negative tumors, suggesting that BCSCs with these mutations may be capable of multilineage differentiation (56) . Importantly, the presence of these mutations was significantly associated with worse relapse-free survival and a shorter median time to relapse.
In conclusion, we have identified two relatively novel genes, RPL39 and MLF2, that affect cells with tumor-initiating properties, as well as lung metastasis. We provide evidence that suggests that RPL39 and MLF2 affect nitric oxide synthase signaling and are altered by hypoxia. The role of the tumor microenvironment, specifically the interplay between hypoxia and nitric oxide synthase in breast-cancer initiation and metastasis, should be further studied. 
Materials and Methods

